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Protein disulphide-isomerase (PDI) activity, and the level of immunodetectable PDI protein, were monitored in splenic 
lymphocytes and in BCL, cells during culture in the presence of various activating factors. Bacterial ipopolysaccharide 
stimulated induction of PDI in splenic B cells and BCL, cells. The time-course and specificity of induction indicated that 
the increase in expression of PDI is closely coupled to the final stages of B cell differentiation into antibody-producing 
plasma cells. The system will prove valuable in studies on the control of expression of PDI. 
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1. INTRODUCTION 
Protein disulphide-isomerase (PDI), an enzyme 
found within the e.r. lumen of a wide range of 
eukaryotic cells, catalyzes thiol-disulphide inter- 
change in proteins in vitro and is believed to be 
responsible for the formation of the native set of 
disulphide bonds during secretory protein folding 
at biosynthesis [ 1,2]. The evidence for this 
biological role includes the finding, in several 
systems, that the level of PDI activity undergoes 
developmental changes in parallel with changes in 
the rate of synthesis of a major disulphide-bonded 
protein [3,4] and the observation, both in lym- 
phoma cell lines and fibroblast lines in culture, of 
a quantitative correlation between PDI activity 
and the rate of synthesis of immunoglobulins and 
procollagens, respectively [5,6]. This correlation 
suggests that the expression of PDI is carefully 
regulated, but the mechanism of regulation is 
unknown. 
In the process of differentiation and maturation 
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to Ig-secreting plasma cells, B lymphocytes in- 
crease the rate of synthesis of immunoglobulins by 
more than an order of magnitude. This is a promis- 
ing system in which to study the regulation of PDI 
expression, since PDI can catalyze in vitro the for- 
mation of disulphide bonds in immunoglobulin 
assembly [5,7,8], and in mouse lymphoma cell 
lines, there is a 40-fold variation in PDI activity 
with the highest levels of activity being seen in 
highly secretory lines such as MOPC 104E (IgM) 
and Pl (IgGza) [5]. The process of lymphocyte dif- 
ferentiation and maturation has been defined in 
detail, so that a variety of stages, and factors re- 
quired for progress to each stage, can be 
distinguished [9]. 
No direct study of PDI activity through lym- 
phocyte maturation has been reported. We 
demonstrate here that the enzyme is induced by the 
polyclonal B cell activator, bacterial lipopolysac- 
charide (LPS), and that the specificity and time- 
course of this induction suggest that the expression 
of PDI is closely coupled to the final stages of dif- 
ferentiation to the secreting plasma cell. A 
preliminary account of this work has been 
presented [lo]. 
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2. MATERIALS AND METHODS 
Bovine protein disulphide-isomerase was purified to 
homogeneity [l 11. A rabbit was injected a total of 7 times with 
0.5 mg of purified enzyme mixed 1: 1 with Freund’s complete 
adjuvant. The resultant antiserum (J3B) was stored in 1 ml ali- 
quots at -20°C. For immunoblotting, SDS-PAGE gels were 
electroeluted onto nitrocellulose filters either at 100 mA over- 
night, or at 250 mA for 3-4 h, in 25 mM Tris, 0.2 M glycine 
containing 20% (v/v) methanol. Blots were developed using 
J3B at a dilution of 1: 500 in 10 mM Tris-HCl, pH 7.4, 0.82% 
(w/v) NaCl and 0.1% (v/v) Tween 20, followed by anti-rabbit 
IgG horseradish peroxidase conjugate (Sigma) at a dilution of 
1:750. Foetal calf serum was used to block excess ites; see [12] 
for details. 
For ELISA, homogeneous bovine PDI was dissolved in 
sodium carbonate buffer (0.05 M, pH 9.6) to a concentration 
of lO/cg/ml and 0.1 ml aliquots were applied in duplicate to 
wells of a micro-ELISA plate, followed by doubling dilutions 
to generate a standard curve. The concentration of PDI in cell 
sonicates was directly assayed by sensitizing the microtitre 
plates with aliquots of sonicate in the same buffer, by overnight 
incubation at 4°C or by incubation for 3-4 h at 37°C in a moist 
airtight box. Wells were washed twice with lcr/, (w/v) BSA and 
0.5% (v/v) Tween 20 in PBS (0.14 M NaCl, 2.7 mM KCl, 
1.5 mM KHsP04, 8.1 mM NazHPOd, pH 7.2) and blocked by 
incubation for 1 h at 37°C with 0.2 ml per well of 1% (w/v) 
BSA in PBS. A 200 pl aliquot of antiserum (J3B) diluted 1: 500 
was added to each well. After a two further washes with the 
above washing buffer, 0.1 ml of second antibody (as for im- 
munoblotting) was added per well and incubated for 1 h at 
37°C. Wells were washed once, 0.1 ml of substrate solution was 
added and after lo-30 min 0.05 ml of 12.5% HaSO4 was added 
to terminate reaction, and plates were read with a Dynatech 
automatic plate reader with a 490 nm filter. Substrate solution 
comprised 40 mg of o-phenylene-diamine dissolved in pH 5 
buffer (26 ml 0.2 M NasHPOd, 24 ml 0.1 M citric acid and 
distilled water to 100 ml) plus 0.02 ml Hz02 added immediately 
before use. 
For cell culture, a cell suspension was prepared from the 
spleens of 15 BALB/c mice by standard methods, cells were 
centrifuged at 200 x g for 6 min and resuspended in 30 ml 
0.83% (w/v) N&Cl for 5 min at room temperature. Cells were 
recentrifuged, resuspended in PBS, counted and recentrifuged. 
For stimulation of T cells with Con A, the celh were resuspend- 
ed (2 x lo6 cells/ml) in standard culture medium (RPM1 1640 
supplemented with 5% (v/v) foetal calf serum, amino acids, 
penicillin (0.06 mg/ml), streptomycin (0.1 mg/ml), glutamine 
(0.3 mg/ml) and &mercaptoethanol (5 x lo-’ M)) plus Con A 
(2 yg/ml). For B cell stimulation, the washed, red cell-depleted 
spleen cells were resuspended (10’ cells/ml) in the standard 
culture medium above. To 50 ml of cell suspension, 5 ml of 
guinea pig serum (a source of lytic complement activity) and 
0.15 ml of the mouse monoclonal anti-Thy-l antibody NIM-RI 
[13] were added and this suspension was incubated at 37°C for 
45 min. The cells were centrifuged, washed in PBS as above and 
the final T cell-depleted B cells were resuspended in the tissue 
culture medium at lo6 cells/ml. For LPS stimulation, LPS was 
added to 0.05 mg/ml and the cells were cultured in 50 ml ali- 
quots as above. Other batches of splenic B cells were stimulated 
with IL-4 with or without submitogenic concentrations 
358 
(2,~g/mI) of affinity-purified goat anti-mouse Ig. The IL-4 
preparation was an IL-4 enriched tissue culture supernatant ob- 
tained from the T cell hybridoma T-Ova (O’Garra, A. and 
Sanderson, C., unpublished). The B-cell lymphoma BCLi was 
maintained in vivo and T cell-depleted cell suspensions were 
stimulated in vitro with LPS or with IL-4 from T cell 
hybridoma T-Ova [ 141. 
AI1 cultures were divided into 50 ml aliquots in individual 
flasks which were incubated at 37°C for O-4 days. At each time 
point a flask was removed and rapidly frozen by immersion in 
a bed of solid CO2. For subsequent analysis the cell suspensions 
were thawed, diluted in 3 vols of TKM buffer (50 mM Tris- 
HCI, pH 7.5, 25 mM KCI, 5 mM MgCls) and sonicated in an 
ice-bath using an MSE 150 probe sonicator at peak-to-peak 
amplitude of 5-7 pm, for 3 bursts of 15 s with 15 s cooling in- 
tervals. The sonicates were assayed for protein [15], for PDI 
protein by ELISA (see above) and for PDI activity by the stan- 
dard assay involving reactivation of incorrectly oxidised 
(scrambled) bovine pancreatic ribonuclease [16,17]. 
3. RESULTS 
The polyclonal rabbit antiserum raised against 
homogeneous bovine PDI (J3B) was found to 
detect this antigen at levels down to 1 ng and to 
cross-react with PDI from a wide range of higher 
eukaryotes 131. It detected a single protein band on 
Western blots of microsomal membranes from rat 
liver and dog pancreas, and was used in a detailed 
study of the distribution of several proteins be- 
tween various endo-membranes in the dog pan- 
creas [18]. The anti-bovine PDI antiserum 
cross-reacted with a protein of 59 kDa in prepara- 
tions of ‘reticuloplasm’ [19] (i.e., e.r. lumenal con- 
tent) from MOPC 315 cells, and was used to 
demonstrate the e.r. location of this protein by 
confocal laser immunofluorescence (Mater, 
D.R.J. and Koch, G.L.E., personal communica- 
tion). With an antiserum provided by Dr M. Green 
(St. Louis University School of Medicine) and rais- 
ed against a major MOPC 315 e.r. protein termed 
ERp59 [20], we observed similar specificity to that 
of our anti-PDI antiserum (fig. 1) demonstrating 
that ERp59 is PDI. The antiserum (J3B) therefore 
cross-reacted well with mouse PDI, which enabled 
both PDI activity and PDI protein to be quan- 
titated in response to various treatments. 
Mouse spleen lymphocytes were cultured in the 
presence and absence of various activating factors. 
Preliminary results indicated that 3-day B cell 
cultures stimulated with bacterial lipopolysac- 
charide (LPS) showed a 1.4- to 2.2-fold increase in 
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Fig. 1. Cross-reactivity between anti-bovine PDI antiserum and 
murine ERp59. Samples of 5 pg purified bovine PDI (lanes 
1,3,5) and 50 fig rat liver microsomal membranes (lanes 2,4,6) 
were resolved by SDS-PAGE and blotted onto nitrocellulose. 
Blots were then developed, as described in section 2, using anti- 
bovine PDI antiserum J3B (lanes 1,2) and antisera raised 
against specific endoplasmic reticulum proteins ERp59 (lanes 
3,4) and ERp61 (lanes 5,6) purified from murine plasmacytoma 
(MOPC-315) cells. The latter antisera [22] were kindly supplied 
by Dr M. Green of St Louis University School of Medicine, and 
were used at a dilution of 1: 250. 
Fig.2. Time course of induction of protein disulphide-isomerase 
by LPS. Splenic B cells and BCli cells were isolated and 
cultured in the presence either of LPS or of Con A for O-4 
days, frozen, thawed and sonicated, as described in section 2. 
The sonicated samples were assayed for total protein, for PDI 
activity, and for PDI antigen by ELISA. (a) PDI specific 
activity, and (b) relative PDI antigen concentration, as a 
function of time of culture. PDI activity data are means of 
activities determined on duplicate cell samples from the same 
time point, ELISA data are means of duplicate dilutions of the 
same cell samples. (m) Spleen cells in presence of Con A; (A) 
splenic B cells in presence of LPS; (A) BCli cells in presence of 
LPS. 
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PDI activity not observed in control or in Con A- 
stimulated T cells. The results of a time-course 
study over 4 days are shown in fig.2a. Both splenic 
B cells and BCLi cells show significant increases in 
PDI activity when cultured with LPS (4.3- and 
4.6-fold, respectively) with most of the increase oc- 
curring between day 3 and day 4. Con A-treated 
splenic T cells showed little increase (1.3-fold): 
BCLi cells treated with the IL-4 enriched T cell 
supernatant showed an intermediate response 
(2.3-fold increase, not shown). Parallel ELISA 
studies on the same samples showed that the LPS 
treatment produced an increase in PDI content in 
both B lymphocytes and BCLi cells which could 
account for the increase in PDI activity; again the 
major effect was noted between days 3 and 4 of 
culture (fig.2b). 
By contrast o the effect of LPS, PDI was not in- 
duced by factors which cause B cell excitation and 
proliferation, but without producing full differen- 
tiation into Ig-secreting plasma cells. Thus goat 
anti-mouse p-chain antibodies and IL-4 enriched T 
cell supernatants had no significant effect on 
-l 
I I I I I , * 3 4 
Days 
Fig.3. Effects of various treatments on PDI activity in cultured 
lymphocytes. Isolated splenic B cells were cultured in presence 
of IL-4 enriched supernatant from T-Ova cells (0), or of goat 
anti-mouse p-chain antibodies (0) or of both of these agents 
(m). Cells were cultured, isolated, sonicated and assayed for 
PDI activity as described in section 2. For comparison, data on 
LPS treatment of splenic B cells from fig.% are also included 
(A). 
spleen cell PDI levels when included separately and 
together in cell cultures (fig.3). 
4. DISCUSSION 
The process of activation of B lymphocytes is 
complex and involves interaction between cell 
types through the production of various specific 
activating factors. In the physiological activation 
process, three successive stages of activation, pro- 
liferation and differentiation to Ig-secreting cells 
can conveniently be distinguished [21] and lym- 
phokines and other factors capable of stimulating 
each of these steps can be identified [9]. 
Two models of B-cell activation to secretion 
were tested. The better known is stimulation of 
resting splenic B lymphocytes by bacterial 
lipopolysaccharide (LPS) [22], which yields 
lo-20% of Ig-secreting cells by day 4 (d4) of 
culture. A particular advantage of this system is 
that at earlier times, when activation (dl) and pro- 
liferation (d2-d3) can be demonstrated, there are 
few Ig-secreting cells. The observation of a major 
increase in PDI at d4 of LPS-activated B cells, and 
not d4 of Con A-activated T cells, thus correlates 
with the appearance of Ig-secreting cells in culture. 
The necessary development of secretion as well as 
activation and proliferation was implicated by the 
insignificant change in PDI activity in B cells ac- 
tivated under conditions that do not yield Ig secre- 
tion. Stimulation of B cells with IL-4 alone results 
in activation (enlargement and increased surface 
expression of Class II antigen), whereas the 
simultaneous presence of IL-4 and sub-mitogenic 
amounts of anti-Ig causes activation and prolifera- 
tion, but does not drive the cells into Ig secretion 
[9]. As demonstrated, B cells stimulated with IL-4, 
with or without goat anti-mouse p-chain, did not 
develop the elevated PDI levels noted in the LPS- 
activated cultures, even when cultured for 4 days. 
Our second model of B cell stimulation was pro- 
vided by the murine B cell lymphoma BCLi. This 
cell line will proliferate in response to both IL-4 
and LPS and, with LPS, will also differentiate into 
Ig-secreting cells [23,24]. In total agreement with 
the results obtained with the first system, a major 
increase in PDI activity was observed in BCLi cells 
stimulated under conditions giving rise to im- 
munoglobulin secretion but not when only pro- 
liferation was induced. 
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Hence, both the specificity and the time-course 
of induction of PDI by LPS-treatment, link the in- 
crease in PDI activity to the final stages of B cell 
differentiation when immunoglobulin synthesis 
and secretion are increased. As noted above, there 
is already abundant evidence that PDI can act in 
vitro to catalyse disulphide bond formation in Ig 
folding and assembly, and that PDI is present at 
high levels in lymphoma-derived cell lines actively 
secreting immunoglobulins. PDI is located within 
the lumen of the endoplasmic reticulum [25] the 
site of immunoglobulin folding and assembly [26]. 
Furthermore, PDI can be chemically cross-linked 
to nascent immunoglobulins in hybridoma cells 
[27]. All these results imply that PDI acts as 
catalyst of immunoglobulin folding and assembly 
in vivo, and the specific induction of PDI 
demonstrated here is consistent with that proposal. 
Another lumenal protein has been implicated in 
facilitating immunoglobulin assembly, namely BiP 
(heavy-chain binding protein, or glucose-fegulated 
protein 78) [28]. With an anti-BiP antiserum kind- 
ly provided by Dr Hugh Pelham (Laboratory of 
Molecular Biology, Cambridge) we have 
demonstrated by Western blotting that BiP levels 
increase in parallel with those of PDI during 
culture of spleen cells in presence of LPS (not 
shown). One of the major morphological conse- 
quences of differentiation to the plasma cell and 
induction of Ig-secretion is extensive proliferation 
of the e.r. and secretory apparatus. Green and col- 
leagues [20,29] described several major e.r. pro- 
teins whose synthesis was induced by 48-h culture 
in presence of LPS, including one Erp59, which we 
have now identified as PDI. They studied the 
biosynthesis and accumulation of these proteins 
(ERp99, ERp72, ERp60, ERp59 and ERp49) and 
noted that their accumulation was matched by a 
correspondingly increased rate of biosynthesis, im- 
plying that all control was exerted at synthesis. 
Taken together with our findings on increases in 
PDI (and BiP) levels over 4 days of LPS induction, 
these results imply that a family of e.r. proteins are 
coinduced by LPS. This family appears to corre- 
spond to the ‘reticuloplasmins’ defined by Koch 
[19] i.e. the permanent resident proteins of the e.r. 
lumen. 
The LPS-stimulated lymphocyte is clearly a 
specialised system, but nevertheless the data 
presented here show that it will be an extremely 
useful model in which to study the control of ex- 
pression of PDI, and the manner in which the level 
of PDI in cells is controlled in parallel to their rate 
of synthesis of disulphide-bonded proteins. 
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